“…An increased risk of thrombophilia under high-dose oestrogen treatment has been discussed, and sporadically deep thrombosis associated with this therapy was reported [4,21]. Failure of reproductive function or association with malignancies as long-term side-eects in women have not been reported but adequate data are missing.…”
Our results show that the BP method gives acceptable adult height predictions in girls, but less accurate predictions in boys. The treatment with high doses of sex hormones was low effective in both sexes and showed a wide range of response. For success, treatment must be initiated in early puberty and terminated late. The answers to a questionnaire revealed no major psychological or social maladjustment of treated individuals compared to those untreated.
“…An increased risk of thrombophilia under high-dose oestrogen treatment has been discussed, and sporadically deep thrombosis associated with this therapy was reported [4,21]. Failure of reproductive function or association with malignancies as long-term side-eects in women have not been reported but adequate data are missing.…”
Our results show that the BP method gives acceptable adult height predictions in girls, but less accurate predictions in boys. The treatment with high doses of sex hormones was low effective in both sexes and showed a wide range of response. For success, treatment must be initiated in early puberty and terminated late. The answers to a questionnaire revealed no major psychological or social maladjustment of treated individuals compared to those untreated.
“…In most studies, unwanted side effects have been reported only during treatment or shortly after discontinuation of therapy (109,112,113,127,128,130,131,183,189,196,197). Most side effects were found to be mild and reversible (see Table 9).…”
Section: Other Adverse Effectsmentioning
confidence: 99%
“…This would suggest a dose-dependent effect of estrogens on the incidence of adverse events (107,130). Although hemostatic changes have been reported (196,200,201), thrombosis is found to be a very uncommon side effect of height-reductive therapy (112,132,196). Whenever thrombosis occurred it usually coincided with other risk factors for thromboembolism such as immobilization (202).…”
“…Estro gen treatment is offered for that reason with good toler ance [6], Well-known common side effects during therapy are nausea, edema, weight gain, headache, vomiting and hypermenorrhea [2, 6. 7], Until now there has been only one report about severe deep venous thrombosis during estrogen treatment for tall stature that happened during a short period of immobilisation [8]. We present an addi Clinical Report A 14.6-year-old postmenarcheal girl, a nonsmoker of normal weight, presented with an actual height of 182.5 cm.…”
High-dose estradiol therapy for reduction of final height may be complicated by severe side effects such as deep vein thrombosis. We report a 14.6-year-old girl with tall stature. In order to reduce final height she was treated with ethinylestradiol and medroxyprogesterone. After arthroscopy she suffered acute deep venous thrombosis of her left leg. Despite being monitored at short intervals, coagulation parameters such as AT III and protein C indicated no development of thrombosis. Medical height reduction with estrogen should be accompanied by heparinisation during longer-lasting periods of immobilisation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.